Skip to main navigation
Skip to search
Skip to main content
Region Zealand Home
Help & FAQ
Link opens in a new tab
Dansk
English
Search content at Region Zealand
Home
Profiles
Research units
Projects
Research output
Prizes
Activities
Courses
Press/Media
Impacts
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.
Christoph Stettler
*
, Sabin Allemann
, Simon Wandel
, Adnan Kastrati
, Marie Claude Morice
, Albert Schömig
, Matthias E. Pfisterer
, Gregg W. Stone
, Martin B. Leon
, José Suárez de Lezo
, Jean Jacques Goy
, Seung Jung Park
, Manel Sabaté
, Maarten J. Suttorp
,
Henning Kelbaek
, Christian Spaulding
, Maurizio Menichelli
, Paul Vermeersch
, Maurits T. Dirksen
, Pavel Cervinka
Marco De Carlo, Andrejs Erglis, Tania Chechi, Paolo Ortolani, Martin J. Schalij, Peter Diem, Bernhard Meier, Stephan Windecker, Peter Jüni
Show 9 more
Show less
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Review
›
Research
›
peer-review
Overview
Fingerprint
Fingerprint
Explore the research areas of 'Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.'.
Sort by
Weight
Alphabetically
Keyphrases
Patients with Diabetes
100%
Bare Metal Stent
100%
Without Diabetes
100%
Network Meta-analysis
100%
Collaborative Networks
100%
Overall Mortality
50%
Dual Antiplatelet Therapy
50%
Stent
33%
Hazard Ratio
33%
Drug-eluting Stent
33%
Inconsistency
33%
Sirolimus-eluting Stent
33%
Paclitaxel-eluting Stent
33%
Sirolimus
16%
Target Lesion Revascularization
16%
Revascularization Rate
16%
Embase
16%
MEDLINE
16%
Conference Abstracts
16%
Cochrane Central Register of Controlled Trials
16%
Trialists
16%
Primary Safety
16%
Type 1 Diabetes Mellitus (T1DM)
16%
Stent Implantation
16%
U.S. Food
16%
Indirect Evidence
16%
Mixed Treatment Comparison
16%
Credibility Intervals
16%
One-for-All
16%
Comparison Method
16%
Advisory Panel
16%
Point Target
16%
Bare Metal
16%
Paclitaxel
16%
Nursing and Health Professions
Bare Metal Stent
100%
Stent
100%
Network Meta-Analysis
100%
Rapamycin
42%
Paclitaxel
42%
Dual Antiplatelet Therapy
42%
Hazard Ratio
28%
Drug Eluting Stent
28%
Diabetes Mellitus
14%
Target Lesion Revascularization
14%
Embase
14%
Medline
14%
Cochrane Library
14%
Revascularization
14%
Randomization
14%
Book Review
14%
Food and Drug Administration
14%
Medicine and Dentistry
Diabetes
100%
Network Meta-Analysis
100%
Rapamycin
37%
Antiplatelet
37%
Paclitaxel
37%
Hazard Ratio
25%
Drug-Eluting Stent
25%
Target Lesion Revascularization
12%
Revascularization
12%
Diabetes Mellitus
12%
Comparison Trial
12%
Pharmacology, Toxicology and Pharmaceutical Science
Rapamycin
100%
Antiplatelet
100%
Paclitaxel
100%
Diabetes Mellitus
33%
Comparison Trial
33%